If patients with MASLD are glucagon resistant, it remains to be seen whether glucagon resistance, via a reduction in hepatic lipid catabolism enzymes, contributes to the development of MASLD; or whether MASLD, possibly via hepatocyte fat accumulation modulating GCGR function, causes glucagon resistance. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.